Risperidone Effectiveness with Attentional in Schizophrenic Patients
Sihite, Lenni C.
Amin, Mustafa Mahmud
MetadataShow full item record
Risperidone can be found in studies of schizophrenic patients which is more effective than haloperidol in reducing the total score of positive symptoms and negative symptoms in a dose of 4-8 mg per day. The objective of this study is to determine the benefits of risperidone on attentional improvements, get a picture and information about the use of STROOPTES to assess the improvement of attention. This study is an experimental study, in the form of open label clinical trial one group pretest-posttest design. to assess the effectiveness of risperidone on attention in schizophrenic patients. The result showed that the frequency of males is more common that 20 (66.7%), SMA 23 (76.7%), 25-34 age group of 15 people (50%). From this study it was found that risperidone relationship with attentional values in Table 2 shows the mean value of the first Test Strooptest before given risperidone 18.3 (SD 2.3) and mean Strooptest Test I after administration of risperidone 4 mg IV at week 17.8 (SD 2.4). From the statistical test using the dependent t test of the obtained mean value of p = 0.007 p> 0.05 it indicates no significant differences before the given risperidone on Test I and after administration of risperidone in Test I. Mean values obtained from research Strooptest Test II before being given risperidone 39.5 (SD 2.5) and mean Strooptest Test II after administration of risperidone 4 mg IV at week 38.5 (SD 2.9). From the statistical test using the dependent t-test p-value = 0.0001 obtained by means of P <0.05 it indicates no significant differences after administration of risperidone in the second week of the fourth Test. This indicates significant differences were assessed by means of measuring strooptest. Conclusion is that the results indicated after a four-week study with administration of 4 mg risperidone experienced a significant change in the value of strooptest test I and test II.